Arvinas (ARVN) Projected to Post Earnings on Tuesday

Arvinas (NASDAQ:ARVN) is expected to release its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect Arvinas to post earnings of ($0.55) per share and revenue of $37.2630 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 12:30 PM ET.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Wednesday, November 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.27. The business had revenue of $41.90 million during the quarter, compared to analyst estimates of $29.36 million. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.Arvinas’s revenue for the quarter was down 59.1% compared to the same quarter last year. During the same period last year, the company earned ($0.68) EPS. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Trading Up 4.0%

Shares of ARVN opened at $13.48 on Friday. The stock has a market capitalization of $865.69 million, a P/E ratio of -16.64 and a beta of 1.88. The firm’s fifty day simple moving average is $12.43 and its two-hundred day simple moving average is $10.07. Arvinas has a 12 month low of $5.90 and a 12 month high of $20.38.

Wall Street Analysts Forecast Growth

ARVN has been the subject of a number of research analyst reports. Citigroup raised Arvinas from a “neutral” rating to a “buy” rating and increased their price objective for the company from $10.00 to $15.00 in a report on Tuesday, January 6th. The Goldman Sachs Group reissued a “sell” rating and issued a $6.00 price objective (down previously from $8.00) on shares of Arvinas in a report on Wednesday, October 15th. BTIG Research upped their price objective on shares of Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Barclays increased their target price on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Finally, Stephens boosted their price target on shares of Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, November 10th. Eleven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $16.79.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its stake in Arvinas by 491.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after buying an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of Arvinas by 109.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after acquiring an additional 3,500 shares during the period. Jain Global LLC bought a new position in shares of Arvinas in the 3rd quarter worth approximately $95,000. Virtu Financial LLC purchased a new position in shares of Arvinas in the 3rd quarter valued at approximately $124,000. Finally, Oxford Asset Management LLP boosted its position in shares of Arvinas by 15.5% during the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock valued at $123,000 after purchasing an additional 2,242 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.